Current studentsExisting staffContact us
 

Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo

Simple item page
dc.contributor.authorFarrugia, A.
dc.contributor.authorAtkins, G.
dc.contributor.authorTo, L.
dc.contributor.authorPan, B.
dc.contributor.authorHorvath, N.
dc.contributor.authorKostakis, P.
dc.contributor.authorFindlay, D.
dc.contributor.authorBardy, P.
dc.contributor.authorZannettino, A.
dc.date.issued2003
dc.descriptionCopyright © 2003 American Association for Cancer Research
dc.description.abstractMultiple myeloma (MM) is an incurable B-cell malignancy able to mediate massive destruction of the axial skeleton. The aim of this study was to examine the involvement of the tumor necrosis factor-ligand family member, receptor activator of nuclear factor-B ligand (RANKL), and its naturally occurring antagonist, osteoprotegerin (OPG), in MM biology. Using flow cytometry and two independent anti-RANKL antibodies, we demonstrate RANKL expression in CD38+++CD45+ and CD38+++CD45- myeloma plasma cell (MPC) subpopulations derived from patients with osteolytic MM. In addition, highly purified subpopulations of MPC express mRNA for both transmembrane and soluble RANKL isoforms but lack expression of OPG mRNA and protein. We also show that RANKL expressed by MPC is functional as in vitro coculture of CD38+++CD45+ and CD38+++CD45- MPC subpopulations with peripheral blood mononuclear cells resulted in the formation of multinucleate, tartrate-resistant acid phosphatase-positive osteoclasts-like cells capable of forming typical resorption pits. Furthermore, high expression of membrane-associated RANKL by CD38+++ MPC correlated with the presence of multiple radiological bone lesions in individuals with MM. Together, our data strongly suggest that RANKL expression by MPC confers on them the ability to participate directly in the formation of osteoclast in vivo and extends our knowledge of the involvement of RANKL and OPG in the osteolysis characteristic of this disease.
dc.description.statementofresponsibilityAmanda N. Farrugia, Gerald J. Atkins, L. Bik To, Beiqing Pan, Noemi Horvath, Panagiota Kostakis, David M. Findlay, Peter Bardy, and Andrew C. W. Zannettino
dc.identifier.citationCancer Research, 2003; 63(17):5438-5445
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.orcidAtkins, G. [0000-0002-3123-9861]
dc.identifier.orcidZannettino, A. [0000-0002-6646-6167]
dc.identifier.urihttp://hdl.handle.net/2440/9349
dc.language.isoen
dc.publisherAmer Assoc Cancer Research
dc.source.urihttp://cancerres.aacrjournals.org/cgi/content/abstract/63/17/5438
dc.subjectPlasma Cells
dc.subjectOsteoclasts
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectOsteolysis
dc.subjectCarrier Proteins
dc.subjectMembrane Glycoproteins
dc.subjectRadiography
dc.subjectFlow Cytometry
dc.subjectReverse Transcriptase Polymerase Chain Reaction
dc.subjectGene Expression
dc.subjectRANK Ligand
dc.subjectReceptor Activator of Nuclear Factor-kappa B
dc.titleReceptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications